An exploratory study of administration of cidofovir for adenovirus infection after hematopoietic stem cell transplantation.

An exploratory study of administration of cidofovir for adenovirus infection after hematopoietic stem cell transplantation. - Cidofovir for ADV infection after HSCT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003042

Enrollment

Registered

2010-01-20

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenovirus infection after hematopoietic stem cell transplantation.

Interventions

Intravenous administration of cidofovir, 1mg/kg three times a week for three weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have received hematopoietic stem cell transplantation. 2. Patients with adenovirus infection.

Exclusion criteria

Exclusion criteria: 1. Allergy to cidofovir. 2. The serum creatinine is greater than 1.5 mg/dL, the creatinine clearance is equal to or less than 55 mL/min, or the urine protein is greater than 100 mg/dL. 3. HIV-positive patients. 4. A woman during pregnancy or potential pregnancy. 5. Patients who are recognized as inadaptable for this trial.

Design outcomes

Primary

Measure	Time frame
Changes in viral load at the end of treatment.	—

Secondary

Measure	Time frame
Changes in the symptoms of viral infection at the end of treatment. Survival at two months after the end of treatment. Re-administration of antiviral drugs within 2 months after the end of treatment. Adverse event.	—

Countries

Japan

Contacts

Public ContactAkira Honda

University of Tokyo Hospital Hematology and Oncology

ahonda-spr@umin.org03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026